Sign up

RA Capital Management, L.P.

$11.5B assets · 84 holdings · Q2 2026 · Filed 14 AUG 2026

About RA Capital Management, L.P.’s 13F portfolio

RA Capital Management, L.P. is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , RA Capital Management, L.P. reported $11.5B across 84 US-listed positions (). Its largest position is ASCENDIS PHARMA A/S (ASND) at 24% of the reported book, and its ten biggest holdings make up 60% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.

$11.5B
Assets (13F)
#441
of 8,839 by size
84
Holdings
60%
Top-10 weight
27
Buys
28
Sells
Top holdings · Q2 2026
84 total
#StockPrice% of portfolioSharesValue
1
NASDAQ: ASND
ASCENDIS PHARMA A/S
—
—
24%
10.3M$2.7B
2
NASDAQ: PBLS
PARABILIS MEDICINES INC
—
—
6.9%
28.9M$791.9M
3
NASDAQ: RYTM
RHYTHM PHARMACEUTICALS INC
—
—
6.4%
6.7M$740.2M
4
NASDAQ: PCVX
VAXCYTE INC
—
—
5.8%
11.5M$667.0M
5
NASDAQ: SION
SIONNA THERAPEUTICS INC
—
—
3.8%
9.9M$435.7M
6
NASDAQ: TYRA
TYRA BIOSCIENCES INC
—
—
3.4%
12.2M$389.6M
7
NASDAQ: EWTX
EDGEWISE THERAPEUTICS INC
—
—
3.0%
8.4M$341.0M
8
NASDAQ: NAMS
NEWAMSTERDAM PHARMA CO NV
—
—
2.8%
9.6M$323.7M
9
NASDAQ: COAG
HEMAB THERAPEUTICS HOLDINGS
—
—
2.5%
7.8M$286.8M
10
NASDAQ: SEPN
SEPTERNA INC
—
—
2.0%
7.0M$234.3M
11
NASDAQ: BCAX
BICARA THERAPEUTICS INC
—
—
1.9%
7.3M$215.4M
12
NASDAQ: MLYS
MINERALYS THERAPEUTICS INC
—
—
1.8%
7.7M$207.6M
13
NASDAQ: GHRS
GH RESEARCH PLC
—
—
1.8%
7.6M$205.3M
14
NASDAQ: IRON
DISC MEDICINE INC
—
—
1.6%
2.5M$179.2M
15
NASDAQ: SGP
SPYGLASS PHARMA INC
—
—
1.6%
8.0M$178.6M
16
NASDAQ: ARTV
ARTIVA BIOTHERAPEUTICS INC
—
—
1.5%
18.0M$174.2M
17
NASDAQ: JANX
JANUX THERAPEUTICS INC
—
—
1.5%
11.2M$171.9M
18
NASDAQ: TSHA
TAYSHA GENE THERAPIES INC
—
—
1.4%
23.6M$160.4M
19
NASDAQ: BCRX
BIOCRYST PHARMACEUTICALS INC
—
—
1.4%
15.8M$158.3M
20
NASDAQ: WVE
WAVE LIFE SCIENCES LTD
—
—
1.4%
27.0M$156.7M
21
NASDAQ: NUVL
NUVALENT INC-A
—
—
1.3%
1.2M$153.9M
22
NASDAQ: ABVX
ABIVAX SA-ADR
—
—
1.3%
1.1M$150.9M
23
NASDAQ: ORKA
ORUKA THERAPEUTICS INC
—
—
1.3%
1.6M$148.0M
24
NASDAQ: CLYM
CLIMB BIO INC
—
—
1.3%
11.3M$147.4M
25
NASDAQ: SLDB
SOLID BIOSCIENCES INC
—
—
1.0%
12.0M$120.2M

Showing 1–25 of 84 positions on this page reported in this 13F.

Sector allocation
  • Healthcare87%
  • Financial Services0.1%
Recent activity · vs 2026-03-31
Bought27
  • NewASNDASCENDIS PHARMA A/S—$2.7B
  • NewPBLSPARABILIS MEDICINES INC—$791.9M
  • NewCOAGHEMAB THERAPEUTICS HOLDINGS—$286.8M
  • AddedARTVARTIVA BIOTHERAPEUTICS INC+82.2%$174.2M
  • NewABVXABIVAX SA-ADR—$150.9M
  • NewORKAORUKA THERAPEUTICS INC—$148.0M
  • AddedSLDBSOLID BIOSCIENCES INC+28.9%$120.2M
  • AddedZLABZAI LAB LTD-ADR+0.6%$109.1M
  • AddedXNCRXENCOR INC+7.7%$84.9M
  • NewNTLAINTELLIA THERAPEUTICS INC—$76.6M
Sold28
  • ReducedEWTXEDGEWISE THERAPEUTICS INC−19.5%$341.0M
  • ReducedGHRSGH RESEARCH PLC−0.5%$205.3M
  • ReducedNUVLNUVALENT INC-A−50.8%$153.9M
  • ReducedGERNGERON CORP−32.9%$54.8M
  • ReducedVORVOR BIOPHARMA INC−55.6%$44.2M
  • ReducedAKTSAKTIS ONCOLOGY INC−12.6%$42.4M
  • ReducedOVIDOVID THERAPEUTICS INC−2.0%$28.2M
  • ReducedACETADICET BIO INC−21.1%$8.1M
  • ReducedHOWLWEREWOLF THERAPEUTICS INC−64.3%$859K
  • ReducedPTNPALATIN TECHNOLOGIES INC−11.3%$670K
5%+ Beneficial Ownership Stakes · 23 activist (13D) · 57 passive (13G)

Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.

#StockType% of classSharesFiled
1
ARTV
ARTIVA BIOTHERAPEUTICS, INC.
13D37.9%18.4MFiled 23 JUL 2026
2
CLYM
Climb Bio, Inc.
13D33.0% · 2 classes23.9MFiled 09 NOV 2026
3
PEPG
PEPGEN INC.
13D30.5% · 2 classes28.7MFiled 17 NOV 2026
4
ABOS
ACUMEN PHARMACEUTICALS, INC.
13D29.5% · 2 classes21.1MFiled 17 MAR 2026
5
ACRV
ACRIVON THERAPEUTICS, INC.
13D28.8%12.3MFiled 23 APR 2026
6
SGP
SPYGLASS PHARMA, INC.
13D24.1%8.0MFiled 17 FEB 2026
7
PBLS
Parabilis Medicines, Inc.
13D23.8%28.9MFiled 18 JUN 2026
8
SION
SIONNA THERAPEUTICS, INC.
13D22.6% · 2 classes10.1MFiled 07 NOV 2025
9
TYRA
TYRA BIOSCIENCES, INC.
13D21.2% · 2 classes12.3MFiled 06 MAR 2026
10
VOR
VOR BIOPHARMA INC.
13D19.9% · 2 classes12.9MFiled 21 JUL 2026
11
JANX
JANUX THERAPEUTICS, INC.
13D19.9%12.0MFiled 10 MAR 2025
12
WVE
WAVE LIFE SCIENCES LTD.
13D17.1% · 3 classes34.2MFiled 17 APR 2026
13
COAG
Hemab Therapeutics Holdings, Inc.
13G16.6%7.7MFiled 11 MAY 2026
14
BBTX
Bambusa Therapeutics, Inc.
13D14.6%7.4MFiled 06 NOV 2026
15
HOWL
WEREWOLF THERAPEUTICS, INC.
13D13.8%6.7MFiled 06 NOV 2025
16
LENZ
LENZ THERAPEUTICS, INC.
13D13.6%4.3MFiled 07 NOV 2025
17
SEPN
SEPTERNA, INC.
13D11.8%5.5MFiled 14 AUG 2026
18
BCAX
BICARA THERAPEUTICS INC.
13D11.5%7.3MFiled 02 MAR 2026
19
SPRY
ARS PHARMACEUTICALS, INC.
13D11.1%10.9MFiled 01 OCT 2025
20
GERN
GERON CORPORATION
13G9.9% · 2 classes66.5MFiled 14 AUG 2026
21
TSHA
TAYSHA GENE THERAPIES, INC.
13G9.9% · 2 classes32.8MFiled 16 NOV 2026
22
IVVD
Invivyd, Inc.
13G9.9% · 2 classes21.3MFiled 29 AUG 2025
23
PALI
Palisade Bio, Inc.
13G9.9% · 2 classes20.9MFiled 16 NOV 2026
24
IPSC
Century Therapeutics, Inc.
13G9.9%17.9MFiled 16 JAN 2026
25
RZLT
Rezolute, Inc.
13G9.9%15.3MFiled 18 DEC 2025

Showing 1–25 of 80 disclosed stakes. 10 last disclosed over a year ago (the holder may since have dropped below 5%).

Reading RA Capital Management, L.P.’s 13F portfolio

RA Capital Management, L.P.’s $11.5B 13F book is spread across 84 reported positions and is highly concentrated — its ten largest positions alone are 60% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are ASND, PBLS, RYTM, PCVX and SION, led by ASCENDIS PHARMA A/S (ASND) at 24% of the portfolio. The heaviest sector exposure is Healthcare (87%), then Financial Services (0%).

What RA Capital Management, L.P. changed last quarter

Between 2026-03-31 and Q2 2026, RA Capital Management, L.P. was roughly balanced between buying and selling: it opened 17 new positions and added to 10 more, while trimming 10 and closing 18 outright. Against a 84-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was ASCENDIS PHARMA A/S (ASND), and its biggest reduction was EDGEWISE THERAPEUTICS INC (EWTX).

What a 13F does and doesn’t reveal

A 13F captures only RA Capital Management, L.P.’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names RA Capital Management, L.P. is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.

Frequently asked questions

What is an SEC 13F filing?

A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. RA Capital Management, L.P.'s profile on this page is built directly from those filings.

How current is the 13F data on RA Capital Management, L.P.'s page?

It reflects RA Capital Management, L.P.'s most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When RA Capital Management, L.P. files its next quarterly report, this page refreshes automatically.

Can I see RA Capital Management, L.P.'s complete list of holdings?

This page highlights RA Capital Management, L.P.'s largest positions rather than all 84 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under RA Capital Management, L.P.'s filings.

Does a 13F show everything RA Capital Management, L.P. owns?

No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of RA Capital Management, L.P.'s book rather than its full strategy or total assets.

Is 13F data investment advice?

No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why RA Capital Management, L.P. made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.

Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.